Pollution

The Environmental Protection Agency proposed Friday to relax air pollution limits on ethylene oxide, a chemical classified as a human carcinogen since 2016 and used to sterilize medical equipment including catheters and syringes. The EPA stated that current Biden-era standards "actively threaten" manufacturers' abilities to sterilize equipment and jeopardize domestic medical device supply chains. Public health advocates, including the Alliance of Nurses for Healthy Environments, warned that people living near commercial sterilization facilities face elevated lifetime cancer risks, while medical device manufacturers argue the standards could disrupt critical supplies. The proposal marks the latest EPA action under President Donald Trump to relax pollution limits and reduce costs for industry.

The EPA proposed on March 13, 2026, to relax air pollution standards for ethylene oxide used in sterilizing medical devices like catheters and syringes, reversing Biden-era cancer risk findings. The agency cites threats to domestic supply chains for essential equipment. Industry leaders like Scott Whitaker of the Advanced Medical Technology Association praised the move for ensuring uninterrupted sterile supplies while protecting communities. The change aligns with broader Trump EPA efforts to cut industry costs, with public comments expected next.

The EPA proposed on March 13 to relax air pollution standards for ethylene oxide (EtO), a carcinogen used to sterilize medical devices like catheters and syringes, reversing Biden-era rules citing supply chain risks. The agency claims current limits threaten domestic production of essential equipment. Industry groups praise the move for ensuring sterile supplies without interruptions. Critics worry about cancer risks to nearby communities, as seen in past closures like Sterigenics in Illinois.

The EPA proposed weakening pollution standards for ethylene oxide, a carcinogen used to sterilize medical devices like catheters and syringes, reversing Biden-era rules citing threats to domestic supply chains. The move addresses concerns over manufacturing disruptions but draws criticism for elevating cancer risks near 23 U.S. facilities. Classified as a human carcinogen since 2016, the chemical poses lifetime cancer risks to nearby residents, per health advocates. Public comments are expected before finalization amid industry and environmental tensions.